CA
NZ
UK
AU
IND
US
Experts unanimously assert that splitting this vaccine lacks scientific precedent and poses substantial risks to public health. The proposal aims to provide parents with more vaccinationOptionsbut ultimately may lead to decreased immunity among children, raising concerns about potential outbreaks of these preventable diseases. Investors …
This revenue miss comes against a backdrop where analysts had anticipated stability, following a previous quarter’s EPS of $-0.22, compared to a consensus of $-0.18. Investors reacted positively, as TCRX shares gained 1.7% to $0.79 in pre-market trading, despite the year-to-date decline of 23.8% …
Unicycive Therapeutics (NASDAQ: UNCY) disclosed a second‑quarter loss that was markedly lower than the same period a year earlier, reflecting tighter cost management and a stronger cash position. The company now maintains marketable securities of $61.4 million and cash equivalents of $29,198, supporting operations …
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has bolstered its intellectual property portfolio with the issuance of US Patent No. 12,697,190.
Mobia Medical (NASDAQ: MOBI) reported second‑quarter revenue of $13.5 million, a 102% increase from the $6.7 million earned a year earlier, as Vivistim adoption accelerated across stroke‑recovery centers.Earnings Per Sharecame in at $‑0.88 versus a consensus estimate of $‑0.66, underscoring the cost pressures of …
This rise is attributed largely to the acquisition of five skilled nursing facilities in June 2026, which added 639 licensed beds to its portfolio. The significant revenue boost reflects the company’s strategy of expansion and diversification, which is likely to resonate positively among investors …
- Stronger demand for neurostimulation therapy for epilepsy is indicated by a recent guidance update. - Revenue growth is primarily driven by the broader adoption of the RNS therapy, especially for patients with focal epilepsy. - Non-GAAP operating expenses rose due to higher personnel …
NRC Health disclosed a senior‑level executive transition, naming a new chief executive to steer its health‑information platform. The filing, made to the U.S. Securities and Exchange Commission, fulfills the disclosure obligations set out in the Securities Exchange Act of 1934. By announcing the change, …
Pliant Therapeutics (NASDAQ: PLRX) reported a net loss of $22.4 million for the quarter ended June 30, 2026.
Sanofi's decision to discontinue its development of Amlitelimab, a candidate for moderate-to-severe atopic dermatitis, reflects a significant shift in itsResearch and Developmentstrategy. This move came to light on July 24, as the drug failed to demonstrate sufficient efficacy and safety for global regulatory submissions. …
Please wait processing your request...